PH12022553118A1 - Treatment of conditions associated with thyroid hormone - Google Patents

Treatment of conditions associated with thyroid hormone

Info

Publication number
PH12022553118A1
PH12022553118A1 PH1/2022/553118A PH12022553118A PH12022553118A1 PH 12022553118 A1 PH12022553118 A1 PH 12022553118A1 PH 12022553118 A PH12022553118 A PH 12022553118A PH 12022553118 A1 PH12022553118 A1 PH 12022553118A1
Authority
PH
Philippines
Prior art keywords
conditions associated
thyroid hormone
treatment
compositions
treating
Prior art date
Application number
PH1/2022/553118A
Other languages
English (en)
Inventor
Linzy O Scott
Original Assignee
Linzy O Scott
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Linzy O Scott filed Critical Linzy O Scott
Publication of PH12022553118A1 publication Critical patent/PH12022553118A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2022/553118A 2020-04-22 2021-04-22 Treatment of conditions associated with thyroid hormone PH12022553118A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063013960P 2020-04-22 2020-04-22
US202063088523P 2020-10-07 2020-10-07
US202163135118P 2021-01-08 2021-01-08
PCT/US2021/028675 WO2021216896A1 (en) 2020-04-22 2021-04-22 Treatment of conditions associated with thyroid hormone

Publications (1)

Publication Number Publication Date
PH12022553118A1 true PH12022553118A1 (en) 2023-04-03

Family

ID=78270024

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/553118A PH12022553118A1 (en) 2020-04-22 2021-04-22 Treatment of conditions associated with thyroid hormone

Country Status (12)

Country Link
US (1) US20230149410A1 (enExample)
EP (1) EP4138809A4 (enExample)
JP (1) JP2023522956A (enExample)
KR (1) KR20230015906A (enExample)
CN (1) CN115916177A (enExample)
AU (1) AU2021260956A1 (enExample)
BR (1) BR112022021420A2 (enExample)
CA (1) CA3175608A1 (enExample)
IL (1) IL297453A (enExample)
MX (1) MX2022013140A (enExample)
PH (1) PH12022553118A1 (enExample)
WO (1) WO2021216896A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025522112A (ja) * 2022-07-11 2025-07-10 プリズム・エルエルシー アラン・ハーンドン・ダドリー症候群を治療するための方法
CA3261855A1 (en) * 2022-07-11 2024-01-18 PriZm, LLC METHODS AND FORMULATIONS OF GENE THERAPY, AND OF COMBINATION OF GENE THERAPY WITH DITPA THERAPY, FOR ALLAN-HERNDON-DUDLEY SYNDROME
US20240350591A1 (en) * 2023-04-12 2024-10-24 Xygenyx Inc. Composition and methods of treatment using synergistically-enhanced supplementation
CN121910745B (zh) * 2026-03-23 2026-05-26 暨南大学 N-乙酰神经氨酸在制备治疗甲基苯丙胺成瘾的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1243101A (en) * 1999-10-28 2001-05-08 Cary Pharmaceuticals Inc. High dose folic acid for the treatment of hyperhomocysteinemia
IT1320776B1 (it) * 2000-08-07 2003-12-10 Giampiero Valletta Composizione farmaceutica a base di un'associazione vitaminica per laterapia delle cefalee primarie
HRP20160406T1 (hr) * 2009-07-10 2016-05-20 Linzy O. Scott Iii Postupci i pripravci za liječenje sa štitnjačom povezanih medicinskih stanja sa sniženiim folatima
WO2012171065A1 (en) * 2011-06-17 2012-12-20 Esra Ogru Treatment of allan-herndon-dudley syndrome with 3,5-diiodothyropropionic acid (ditpa).
US10640748B2 (en) * 2014-12-24 2020-05-05 Neuorphan Pty Ltd Oligodendroglial cell culturing methods and in methods for treating neurodegenerative disorders by using thyroid hormones or analogues
US20160339086A1 (en) * 2015-05-19 2016-11-24 Suzy Cohen Compositions and methods for treating thyroid disease

Also Published As

Publication number Publication date
EP4138809A1 (en) 2023-03-01
MX2022013140A (es) 2022-11-16
EP4138809A4 (en) 2024-05-01
CA3175608A1 (en) 2021-10-28
CN115916177A (zh) 2023-04-04
US20230149410A1 (en) 2023-05-18
KR20230015906A (ko) 2023-01-31
AU2021260956A1 (en) 2022-11-17
IL297453A (en) 2022-12-01
WO2021216896A1 (en) 2021-10-28
BR112022021420A2 (pt) 2022-12-27
JP2023522956A (ja) 2023-06-01

Similar Documents

Publication Publication Date Title
MX2022013140A (es) Tratamiento de afecciones asociadas con la hormona tiroidea.
MX2024006123A (es) Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo.
MX2021011488A (es) Compuestos y usos de estos.
IL143313A0 (en) Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases
MX2022011550A (es) Composiciones y métodos para inhibir la expresión de angptl3.
PH12021552024A1 (en) Treatment of kidney injury
PH12021552763A1 (en) Treatment and prevention of metabolic diseases
WO2019246262A3 (en) Methods of treating or inhibiting onset of huntington's disease
MX2024003145A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2010003548A (es) Metodos para el tratamiento de padecimientos neurologicos autoinmunes con ciclofosfamida.
MY199903A (en) Combination therapy with controlled-release cnp agonists
FR2706767B1 (enExample)
MX2020009942A (es) Compuestos y usos de los mismos.
PH12021550176A1 (en) Method for treating epilepsy
WO2018209022A3 (en) Methods of treating neuropsychiatric disorders
IL96146A0 (en) Method of treating anxietyrelated disorders using sertraline
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2020003042A (es) Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
MX2025001444A (es) Anticuerpos monoclonales anti-trkb y metodos de uso
WO2019103658A3 (ru) Производные 1,4-бензодиазепин-2-она и их применение
ZA202106809B (en) Medium chain triglyceride formulations with improved bioavailiblity and methods related thereto
MX2021008081A (es) Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.
WO2020154571A8 (en) Compounds and uses thereof
MX2023003993A (es) Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina.